TY - JOUR
T1 - Surface engineered excipients
T2 - I. improved functional properties of fine grade microcrystalline cellulose
AU - Chen, Liang
AU - Ding, Xiaoyi
AU - He, Zizhou
AU - Huang, Zhonghui
AU - Kunnath, Kuriakose T.
AU - Zheng, Kai
AU - Davé, Rajesh N.
N1 - Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/1/30
Y1 - 2018/1/30
N2 - Excipients with good flowability, bulk density as well as compaction properties are desired for use in tableting since they play important roles in formulation development and processing, including, handling, mixing, feeding and compaction. The objective of this paper is to examine the feasibility of using dry coating based surface modification of microcrystalline cellulose, Avicel PH-105, to produce an engineered fine grade (<30 μm) excipient that has all three desired properties. Using a material sparing high-intensity vibrational mixer, Avciel PH-105 is dry coated with 1 wt% Aerosil 200, selected due to its relatively higher dispersive surface energy and lower particle size amongst other silica choices. The results indicated that as expected, the bulk density and flowability are significantly improved, while there was an appreciable loss of compaction. To minimize the loss of compaction, attributed to decreased surface energy after coating, while maintaining improved bulk density and flowability, the effect of reduced silica amount was examined. Remarkably, at reduced levels (0.5 wt% to 0.7 wt%) of Aerosil 200, significant improvements in bulk density and flowability were attained with only 9%–12% compaction reduction. The properties of the surface-engineered excipients were compared with several other commercially available pharmaceutical excipients using two different processibility or regime maps; tablet tensile strength versus bulk density or flow function coefficient (FFC). The surface engineered excipients exhibited the best overall performance establishing a promising pathway to engineer excipients using dry processing instead of complex processes such as spray drying.
AB - Excipients with good flowability, bulk density as well as compaction properties are desired for use in tableting since they play important roles in formulation development and processing, including, handling, mixing, feeding and compaction. The objective of this paper is to examine the feasibility of using dry coating based surface modification of microcrystalline cellulose, Avicel PH-105, to produce an engineered fine grade (<30 μm) excipient that has all three desired properties. Using a material sparing high-intensity vibrational mixer, Avciel PH-105 is dry coated with 1 wt% Aerosil 200, selected due to its relatively higher dispersive surface energy and lower particle size amongst other silica choices. The results indicated that as expected, the bulk density and flowability are significantly improved, while there was an appreciable loss of compaction. To minimize the loss of compaction, attributed to decreased surface energy after coating, while maintaining improved bulk density and flowability, the effect of reduced silica amount was examined. Remarkably, at reduced levels (0.5 wt% to 0.7 wt%) of Aerosil 200, significant improvements in bulk density and flowability were attained with only 9%–12% compaction reduction. The properties of the surface-engineered excipients were compared with several other commercially available pharmaceutical excipients using two different processibility or regime maps; tablet tensile strength versus bulk density or flow function coefficient (FFC). The surface engineered excipients exhibited the best overall performance establishing a promising pathway to engineer excipients using dry processing instead of complex processes such as spray drying.
KW - Bulk density
KW - Dry coating
KW - Excipient
KW - Powder flow
KW - Silica
KW - Surface modification
KW - Tensile strength
UR - http://www.scopus.com/inward/record.url?scp=85035795714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035795714&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2017.11.060
DO - 10.1016/j.ijpharm.2017.11.060
M3 - Article
C2 - 29191481
AN - SCOPUS:85035795714
SN - 0378-5173
VL - 536
SP - 127
EP - 137
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1
ER -